Jodie Barr, DO
In the treatment of patients with neuroendocrine tumors (NETs), researchers have made significant strides that can be augmented by the use and development of genetic sequencing and biomarkers, said Jodie Barr, DO, a hematologist/oncologist at Lawrence Memorial Hospital.
“There is a lot we don’t know about the biology of the tumors; they’re very heterogenous,” she explained. “Trying to figure out what is going on genetically with these tumors will help us figure out how to sequence treatment prognostically and really help tailor treatment for...patients.”
In January 2018, the FDA approved Lutathera (lutetium Lu 177 dotatate) for the treatment of patients with somatostatin receptor–positive gastroenteropancreatic tumors following the results of the phase III NETTER-1 trial.
... to read the full story